Clinical Response to Regenerative Therapies for Erectile Dysfunction: A Systematic Review and Meta-Analysis of Responder Outcomes
- 1Department of Urology, JSC “National Scientific Medical Center”, Astana 010000, Kazakhstan
- 2Center of Stem Cell Technology and Transplantation, JSC “National Scientific Medical Center”, Astana 010000, Kazakhstan
- 3Medi-Art Clinic, Astana 010000, Kazakhstan
Abstract
Background/Objectives: Regenerative therapies are increasingly used for organic erectile dysfunction (ED), but their effects on erectile function and clinically meaningful response remain uncertain. We evaluated erectile-function scores, penile hemodynamics, and responder outcomes. Methods: We searched PubMed, Scopus, and Cochrane CENTRAL from January 1999 to June 2026. Controlled, active-comparator, and uncontrolled studies were analysed separately. Random-effects models synthesised continuous and responder outcomes by follow-up period. We assessed risk of bias using RoB 2 and ROBINS-I and rated certainty of evidence using GRADE. Results: We included 46 study reports comprising 18 randomized trials and 28 non-randomized studies. In controlled comparisons, mean International Index of Erectile Function (IIEF) scores favored treatment at short-term follow-up (≤12 weeks; Hedges’ g = 1.08, 95% CI 0.64–1.52). The mid-term estimate was less precise (13–24 weeks; g = 0.49, 95% CI −0.02 to 1.01). Controlled Erection Hardness Score estimates were also imprecise. Risk ratios for study-defined clinically meaningful improvement in the IIEF erectile function domain were 2.51 (95% CI 0.76–8.31), 2.62 (0.56–12.36), and 2.67 (0.58–12.22) at 4, 12, and 24 weeks, respectively. Exploratory within-group analyses showed post-treatment changes in erectile function and peak systolic velocity, with substantial heterogeneity across several analyses. Conclusions: Controlled studies favored regenerative therapies for short-term improvement in mean erectile-function scores. Whether more patients achieve a clinically meaningful response, how long any benefit lasts, and which therapies are most effective remain uncertain. The review was registered with PROSPERO (CRD420261421415).
Related
- Completeness and guideline concordance of artificial intelligence chatbot responses to patient questions on regenerative therapies for erectile dysfunction: a multi-platform analysis.
- Smart Alerting in Smartphone‐Based First Responder Systems and Arrival Before Emergency Medical Services:The ALARM Randomized Clinical Trial
- Intranasal delivery of regenerative biologics for neurological disorders: a systematic review of clinical studies
- Efficacy of nutraceuticals as adjunctive therapies in autoimmune diseases: A systematic review of clinical trials.
- Precision targeting and regenerative therapies in articular cartilage diseases with AI-driven theranostics
BibTeX
@article{omarbayev2026clinical,
title = {{Clinical Response to Regenerative Therapies for Erectile Dysfunction: A Systematic Review and Meta-Analysis of Responder Outcomes}},
author = {Rustam Omarbayev and Yerbol Iskakov and Aliya Orassay and Rinat Nugumanov and Saule Paizullayeva and Manarbek Askarov},
journal = {Journal of Clinical Medicine},
year = {2026},
month = nov,
doi = {10.3390/jcm15228895},
url = {https://www.mdpi.com/2077-0383/15/22/8895},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Clinical Response to Regenerative Therapies for Erectile Dysfunction: A Systematic Review and Meta-Analysis of Responder Outcomes
AU - Rustam Omarbayev
AU - Yerbol Iskakov
AU - Aliya Orassay
AU - Rinat Nugumanov
AU - Saule Paizullayeva
AU - Manarbek Askarov
PY - 2026
DA - 2026/11/13
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15228895
UR - https://www.mdpi.com/2077-0383/15/22/8895
AB - Background/Objectives: Regenerative therapies are increasingly used for organic erectile dysfunction (ED), but their effects on erectile function and clinically meaningful response remain uncertain. We evaluated erectile-function scores, penile hemodynamics, and responder outcomes. Methods: We searched PubMed, Scopus, and Cochrane CENTRAL from January 1999 to June 2026. Controlled, active-comparator, and uncontrolled studies were analysed separately. Random-effects models synthesised continuous and responder outcomes by follow-up period. We assessed risk of bias using RoB 2 and ROBINS-I and rated certainty of evidence using GRADE. Results: We included 46 study reports comprising 18 randomized trials and 28 non-randomized studies. In controlled comparisons, mean International Index of Erectile Function (IIEF) scores favored treatment at short-term follow-up (≤12 weeks; Hedges’ g = 1.08, 95% CI 0.64–1.52). The mid-term estimate was less precise (13–24 weeks; g = 0.49, 95% CI −0.02 to 1.01). Controlled Erection Hardness Score estimates were also imprecise. Risk ratios for study-defined clinically meaningful improvement in the IIEF erectile function domain were 2.51 (95% CI 0.76–8.31), 2.62 (0.56–12.36), and 2.67 (0.58–12.22) at 4, 12, and 24 weeks, respectively. Exploratory within-group analyses showed post-treatment changes in erectile function and peak systolic velocity, with substantial heterogeneity across several analyses. Conclusions: Controlled studies favored regenerative therapies for short-term improvement in mean erectile-function scores. Whether more patients achieve a clinically meaningful response, how long any benefit lasts, and which therapies are most effective remain uncertain. The review was registered with PROSPERO (CRD420261421415).
SN - 2077-0383
ER -